📢 Cancers MDPI was awarded an updated Impact Factor of 4.5 in the 2023 Journal Citation Reports released by Clarivate in June 2024. The journal rank has now been upgraded to JCR Q1 (78/322 in the 'Oncology' category, 5-Year Impact Factor: 4.9). 👉 Read more: https://lnkd.in/g7JUNySw
Cancers MDPI
Verlagswesen für Bücher und Zeitschriften
Cancers Editorial Office (IF: 5.2, ISSN 2072-6694) International, Open Access Journal, Covering All Aspects of Oncology
Info
Cancers (ISSN 2072-6694; CODEN: CANCCT) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Cancers features (1) Original Articles reporting on novel and original findings; (2) Clinical Observations accompanied by analysis and discussion; (3) Communications reporting small scale studies that include important new information; (4) timely Reviews and Topical Issues on cutting edge fields in oncology. In addition, we accept well-designed studies showing meaningful but negative results. By doing this, we encourage scientists to share those data so that they would not need to repeat the experiments that somebody else has already done. The scope of Cancers includes (but is not limited to): Cancer pathophysiology Cancer causes Cancer diagnosis Cancer screening Cancer prognosis Cancer prevention, initiation, progression, and treatment
- Website
-
https://www.mdpi.com/journal/cancers
Externer Link zu Cancers MDPI
- Branche
- Verlagswesen für Bücher und Zeitschriften
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- Basel
- Art
- Privatunternehmen
Orte
-
Primär
St. Alban-Anlage 66
Basel, CH
Beschäftigte von Cancers MDPI
-
Ravindra Kumar
Senior Scientist|Computational Biologist|Bioinformatician|Data Analyst|Epigenetics|Machine Learning|Deep Learning|Algorithm Developer|Bioinformatics…
-
Natália Roque, MSc, PhD
Medical Science Liaison | MSL Rare Disease at Sanofi |
-
Meysam Sarshar
Postdoctoral Research Fellow
-
Pritam Sadhukhan
Biologist at National Institutes of Health (USA); Associate Editor at Frontiers in Oncology
Updates
-
🔊We share the #Review "Artificial Intelligence in the Diagnosis and Treatment of Pancreatic Cystic Lesions and Adenocarcinoma" ✍by Joanna Jiang et al. The Ohio State University Wexner Medical Center 📌Link here: https://lnkd.in/eCHaPnu3 Keywords: artificial intelligence; pancreatic ductal adenocarcinoma; pancreatic cysts; endoscopy; IPMN
-
-
🎖Check out the Highly cited #Review "Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer" 👏by Houssein Chhouri, PhD et al. INSERM Access the full paper here▶️ https://lnkd.in/efYxYWjq Keywords: non-small cell lung cancer; targeted therapy; EGFR-TKI; drug resistance; drug tolerant persister cells; cellular barcoding
-
-
📜Today we share the #Review "Long Axial Field-of-View PET/CT Could Answer Unmet Needs in Gynecological Cancers" 🧐by Elizabeth K.A. Triumbari et al. Fondazione Policlinico Universitario Agostino Gemelli IRCCS Find out more here👉 https://lnkd.in/eU2Ud4tZ Keywords: PET/CT; long axial field of view; total body
-
-
Cancers MDPI hat dies direkt geteilt
Excited to share my latest publication on Cancers MDPI on the link between diet quality and quality of life in breast cancer patients, using validated indices. Supported by my amazing epidemiology and biostatistics team, we explore how nutritional choices can impact well-being during cancer treatment
-
📢 New #SpecialIssue “Artificial Intelligence-Assisted Radiomics in Cancer ” guest edited by Dr. Seong K. Mun is open for submissions! 📅 Deadline for manuscript submissions: 20 February 2025. ➡More details: https://lnkd.in/dcbM6y3y #ArtificialIntelligence
-
-
📣 Welcome to read the Highly Cited Papers in 2023 in the Section “Cancer Biomarkers” 🤗 Find more details here: https://lnkd.in/dzzh7VMY #HighlyCitedPaper #CancersMDPI
-
-
📢Happy to share the #SpecialIssue "Updates on Immune Checkpoint Inhibitors in Hepatocellular Carcinoma" edited by Dr. Rodolfo Sacco and Dr. Luca Marzi 🗓️Deadline for manuscript submissions: 30 June 2025 📌Find more details here: https://lnkd.in/d55u5rp5 #CancersMDPI #HepatocellularCarcinoma #ImmuneCheckpointInhibitor
-
-
📣 Check out the Highly Cited Papers in 2023 in the Section “Tumor Microenvironment” 🤗 Find more details here: https://lnkd.in/d9xRDFfF #HighlyCitedPaper #CancersMDPI
-
-
📣 Welcome to read the Highly Cited Papers in 2023 in the Section “Infectious Agents and Cancer” 🤗 Find more details here: https://lnkd.in/drjVxqZP #HighlyCitedPaper #CancersMDPI
-